HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on TransCode Therapeutics (NASDAQ:RNAZ) and maintained a $3 price target, indicating continued confidence in the company's potential.
October 24, 2024 | 11:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on TransCode Therapeutics and maintained a $3 price target, suggesting confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $3 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100